Detection of BCR-ABL T315i Mutation in Imatinib Resistant Chronic Myeloid Leukemia Patients
T315I Mutation Detection in CML Patients
Vol. 14 No. 1 : 2019 (145-156)
Abstract
Chronic myeloid leukemia (CML) patients who have BCR-ABL T315I mutation, usually present in the advance phase of the disease with overall survival (OS) shorter than those without the mutation. This study aimed to determine the prevalence of T315I mutation amongst imatinib mesylate (IM) resistant CML patients and to compare the OS between T315I-mutated and non-T315I-mutated patients. Sixty consecutive CML patients who were treated with IM for at least 18 months and their treatment responses, were recorded. The mutation analysis was done using allele-specific oligonucleotide reverse transcriptase-polymerase chain reaction (RT-PCR) assay followed by direct sequencing technique. Forty-two patients (70%) were found to have IM-resistance. Five out of 42 patients had detectable T315I mutation. Median OS of IM-resistant T315I-mutated patients was 96 months (95% CI:54-138) compared to 84 months (95% CI:48-120) in non T315I-mutated patients, although this was found to be statistically insignificant (p = 0.43). The present study showed a higher prevalence of T315I mutation as compared to a few local studies. Median OS of T315I-mutated patients were observed to be longer than non-T315-mutated patients. Further studies encompassing larger cohort of patients are required to confirm this finding.
Keywords :
BCR ABL,
chronic myeloid leukemia,
T315I mutation,
Correspondance Address
Prof. Dr. Raja Zahratul Azma Raja Sabudin. Department of Pathology, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak, 56000 Cheras, Kuala Lumpur, Malaysia. Tel: +603-91455443. Email: zahratul@ppukm.ukm.edu.my
References
Auewarakul, C.U., Huang, S., Yimyam, M., Boonmoh, S. 2006. Natural history of Southeast Asian chronic myeloid leukemia patients with different BCR-ABL gene variants. Acta Haematologica 116(2): 114-9.
Baccarani, M., Deininger, M.W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J.F., Cervantes, F., Clark, R.E., Cortes, J.E., Guilhot, F., Hjorth-Hansen, H., Hughes, T.P., Kantarjian, H.M., Kim, D.W., Larson, R.A., Lipton, J.H., Mahon, F.X., Martinelli, G., Mayer, J., Müller, M.C., Niederwieser, D., Pane, F., Radich, J.P., Rousselot, P., Saglio, G., Saußele, S., Schiffer, C., Silver, R., Simonsson, B., Steegmann, J.L., Goldman, J.M., Hehlmann, R. 2013. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood 22(6): 872-84
Branford, S., Rudzki, Z., Walsh, S., Grigg, A., Arthur, C., Taylor, K., Herrmann, R., Lynch, K.P., Hughes, T.P. 2002. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99(9): 3472-75.
Chahardouli, B., Zaker, F., Mousavi, S.A., Kazemi, A., Ostadali, M., Nadali, F., Rostami, S., Alimoghaddam, K., Ghavamzade, A. 2013. Evaluation of T315I mutation frequency in chronic myeloid leukemia patients after imatinib resistance. Hematology 18(3): 158-62.
Druker, B.J., Guilhot, F., O’Brien, S.G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M.W., Silver, R.T., Goldman, J.M., Stone, R.M., Cervantes, F., Hochhaus, A., Powell, B.L., Gabrilove, J.L., Rousselot, P., Reiffers, J., Cornelissen, J.J., Hughes, T., Agis, H., Fischer, T., Verhoef, G., Shepherd, J., Saglio, G., Gratwohl, A., Nielsen, J.L., Radich, J.P., Simonsson, B., Taylor, K., Baccarani, M., So. C., Letvak, L., Larson, R.A. 2006. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355(2): 2408-17.
Elias, M.H., Azlan, H., Rosline, H., Sim, G.A., Padmini, M., Fadilah, S.A., Ankathil, R. 2014. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome. Leuk Res 38(4): 454-9
Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P.N., Sawyers, C.L. 2001. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293(5531): 876-80.
Jabbour, E., Kantarjian, H., Jones, D., Talpaz, M., Bekele, N., O’Brien, S., Zhou X, Luthra, R., Garcia-Manero, G., Giles, F., Rios, M.B., Verstovsek, S., Cortes, J. 2006. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20(10): 1767-73.
Jiang, X., Zhao, Y., Smith, C., Gasparetto, M., Turhan, A., Eaves, A., Eaves, C. 2007. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 21(5): 926-35.
Kim, S.H., Kim, D.W., Goh, H.G., Jang, S.E., Lee, J., Kim, W.S., Kweon, I.Y., Park, S.H. 2009. Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent. Hematol Oncol 27(4): 190-7
Mat Yusoff, Y., Abu Seman, Z., Othman, N., Kamaluddin, N.R., Esa, E., Zulkiply, N.A., Abdullah, J., Zakaria, Z. 2018. Prevalence of BCR-ABL T315I mutation in Malaysian patients with imatinib-resistant chronic myeloid leukemia. Asian Pac J Cancer Prev 19(12): 3317-20.
O’Brien, S.G., Guilhot, F., Larson, R.A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J.J., Fischer, T., Hochhaus, A., Hughes, T., Lechner, K., Nielsen, J.L., Rousselot, P., Reiffers, J., Saglio, G., Shepherd, J., Simonsson, B., Gratwohl, A., Goldman, J.M., Kantarjian, H., Taylor, K., Verhoef, G., Bolton, A.E., Capdeville, R., Druke,r B.J. 2003. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348(11): 994-1004.
Roche-Lestienne, C., Soenen Cornu, V., Grardel Duflos, N., Lai, J.L., Philippe, N., Facon, T., Facon, T., Fenaux, P., Preudhomme, C. 2002. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100(3): 1014-8.
Soverini, S., Iacobucci, I., Bacarrani, M., Martinelli, G. 2007. Targeted therapy and the T315I mutation in Philadelphia-positive leukemias. Haematologica 92(4): 437-9.
Vaidya, S., Ghosh, K., Vundinti, B.R. 2011. Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review. Eur J Haematol 87: 381-93.
Valent, P. 2008. Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease. Br J Haematol 142: 361-78.
Wang, L., Giannoudis, A., Lane, S., Williamson, P., Pirmohamed, M., Clark, R.E. 2007. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 83(2): 258-64.
